AGO-OVAR17

Trial Description: 
Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer (BOOST)
Lead Cooperative Group: 
Participating Groups: 
Disease Site: 
Ovarian
Trial Status: 
Follow Up
Contact person: